Intuitive Surgical, Inc. DossierIntuitive Surgical, Inc. reported $2.51 billion in revenue and generated $759.7 million in operating income during the third quarter of fiscal year 2025, driven by worldwide procedure volumes and the commercial adoption of the da Vinci 5 surgical system. The company capitalized on the expanding utilization of its robotic-assisted platforms, securing FDA 510(k) clearance for software updates and advancing its digital ecosystem through new AI-integrated features. Financial Highlights* Third Quarter FY2025 Revenue: $2.51 billion * Operating Income: $759.7 million * Net Income: $704.4 million * Diluted Earnings Per Share: $1.95 * Gross Profit: $1.66 billion * Instruments and Accessories Revenue: $1.52 billion * da Vinci System Placements: 427 units * Cash and Cash Equivalents: $2.25 billion Strategic AnalysisIntuitive Surgical, Inc. continues to solidify its leadership in minimally invasive care through a robust "razor and blades" business model, where recurring revenue from instruments, accessories, and services provides stable cash flow. In the... Sign in / Sign up to learn more about Intuitive Surgical, Inc Continue your research by chatting with our AI financial analyst about Intuitive Surgical, Inc. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings. Start your analysis with these investor-focused questions: - Given that Intuitive Surgical, Inc.'s valuation multiples (e.g., P/E, EV/Revenue) are substantially higher than peers like Medtronic and Stryker, what specific factors in its 'razor and blade' business model and innovation pipeline, such as the da Vinci 5 launch, justify this premium valuation?
- Intuitive Surgical, Inc. guides for 17% to 17.5% procedure growth in FY2025. How do the strategic initiatives around the da Vinci 5 adoption and the expansion of the Ion Endoluminal System contribute to this forecast, and what are the primary execution risks to achieving this growth target?
- With core patents for da Vinci products beginning to expire in 2026, what is the potential impact on Intuitive Surgical, Inc.'s high-margin recurring revenue, and how do the technological advancements in the da Vinci 5 and its AI-driven features strengthen its competitive moat against emerging threats?
- Intuitive Surgical, Inc. projects a strong non-GAAP gross profit margin of 67% to 67.5% for FY2025. What are the key drivers of this profitability, and how might competitive pricing pressure or the costs associated with the global da Vinci 5 rollout impact these margins?
- Considering Intuitive Surgical, Inc.'s strong balance sheet with zero debt and a significant net cash position, how does its FY2025 capital allocation strategy, including a projected $700-$750 million in capex, support its long-term growth versus potential shareholder returns or further strategic acquisitions?
|
